Erica DiNapoli

R. Lor Randall, MD, FACS, discusses the evolving management of desmoid fibromatosis, shares advice on the factors that go into deciding when to treat this disease, and stresses the importance of having a multidisciplinary team involved in the care of these patients.

Bradley G. Somer, MD, discusses shifts in the hepatocellular carcinoma treatment paradigm, pivotal trials that have generated excitement, and sequencing approaches.

Noam VanderWalde, MD, MS, highlights the importance of multidisciplinary care for rectal cancer and few key studies that have impacted treatment.

Debu Tripathy, MD, discusses tucatinib and fam-trastuzumab deruxtecan-nxki as 2 exciting drug approvals in the constantly changing HER2-positive breast cancer treatment paradigm.

Sattva Neelapu, MD, discussed findings from the first-in-human phase 1 ALPHA study which demonstrated encouraging short-term efficacy, along with manageable toxicities, with ALLO-501 and ALLO-647.

Nina Shah MD, discusses the future of CAR T-cell therapy and bispecific antibodies in multiple myeloma.

The phase 3 ADAURA trial continues to generate a lot conversation, debate, and excitement in the lung cancer community after results showed that adjuvant osimertinib showed a statistically significant improvement in disease-free survival in patients with stage IB-IIIA EGFR-positive non–small cell lung cancer, making it the first agent to do so in the space.

Atish D. Choudhury, MD, PhD, sheds light on the nonmetastatic castration-resistant prostate cancer treatment landscape and notable ongoing trials examining antiandrogens in different settings.

Rana R. McKay, MD, discusses the benefit of intense neoadjuvant hormone therapy prior to radical prostatectomy in men with high-risk prostate cancer and next steps for research.

Nikhil Khushalani, MD, discusses cemiplimab-rwlc, which has become the preferred agent for the frontline treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma.

Manfred Welslau, MD, discusses findings from the REFLECT interim analysis that reconfirmed the activity of the rituximab biosimilar SDZ-RTX, in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with diffuse large B-cell lymphoma.

Praful K. Ravi, MD, discusses the emergence of immunotherapies, FGFR inhibitors, and antibody-drug conjugates and how they dramatically evolved the metastatic urothelial cancer treatment paradigm.

Savolitinib demonstrated encouraging efficacy and an improved safety profile over sunitinib in patients with MET-driven papillary renal cell carcinoma.

Elaine Shum, MD, sheds light on osimertinib as the standard of care in the frontline treatment of patients with EGFR-mutant non–small cell lung cancer, which may be on its way to becoming a key player in the adjuvant setting and a promising option to include with novel combinations.

Jeffrey A. Meyerhardt, MD, MPH, FASCO, discusses the addition of celecoxib to standard chemotherapy, stating that it did not significantly improve disease-free survival or overall survival in patients with colon cancer.

Heinz-Josef Lenz, MD, FACP, discusses third-line treatment approaches that are generating excitement in colorectal cancer.

Anthony B. El-Khoueiry, MD, discusses the evolution of HCC treatment, paradigm-shifting trials, and where future research is headed.

Bradley J. Monk, MD, FACS, FACOG, discusses key updates in cervical cancer treatment, exciting ongoing research efforts, and emerging approaches that are shaking up the treatment paradigm.

R. Lor Randall, MD, FACS, discusses preoperative radiotherapy and how it has become a standard of care for patients with soft tissue sarcoma of the extremities; however, postoperative radiation still plays a role in the paradigm, especially when wound risks are considered to be precarious.

Gary K. Schwartz, MD, discusses the clinical findings with the combination of nivolumab and ipilimumab in patients with dedifferentiated liposarcoma and undifferentiated pleomorphic sarcoma.

Jamile M. Shammo, MD, discusses the current treatment landscape of high-risk MDS recent data with the investigational small molecule inhibitor of the NEDD8-activating enzyme pevonedistat, and ongoing research efforts in the space.

Neal Shore, MD, discusses the significantly improved overall survival in patients with nonmetastatic castration-resistant prostate cancer who received darolutamide.

Jennifer Litton, MD, discusses findings from the phase 3 EMBRACA trial on talazoparib in patients with advanced BRCA1/2-positive breast cancer.

Daniel H. Ahn, DO, discusses the slew of actionable alterations that have emerged in colorectal cancer in recent years, including targeted therapies that are boosting survival outcomes.

Tanios S. Bekaii-Saab, MD, FACP, discusses the rapidly changing hepatocellular carcinoma treatment landscape and shares advice on how he navigates among the available options available for these patients.

Madappa Kundranda, MD, PhD, discusses the significance of the NAPOLI-1 and NAPOLI-3 trials in pancreatic cancer, other exciting ongoing research efforts, and key challenges remaining in the space.

Cora N. Sternberg, MD, discusses the data seen with enzalutamide in nonmetastatic castration-resistant prostate cancer, the updated survival results from the phase 3 PROSPER trial, and how she chooses among the agents available in the space.

David Sallman, MD, discusses the combination of eprenetapopt and azacitidine, a new standard of care for patients with myelodysplastic syndromes with a susceptible TP53 mutation.

Harry H. Yoon, MD, discusses how second-line pembrolizumab, followed by any subsequent therapy is associated with longer overall survival in patients with advanced gastric/gastroesophageal junction cancer.

Neal D. Shore, MD, FACS, discusses the pivotal HERO trial, the promising safety data observed with relugolix, and the next steps for the agent in advanced prostate cancer.